Boehringer Ingelheim today announced that Phase II results from LUME-Meso, a randomized, double-blind, placebo-controlled trial, have been presented as part of an Oral Abstract Session at the 2017...

ASMS 2017 – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, strengthened its leadership in mass spectrometry by launching new technologies to advance cutting-edge...

Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced new Phase 1...

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced smart chemotherapy DS-8201 demonstrated a favorable safety profile and promising antitumor activity in patients with...

Poseida Therapeutics, Inc. ("Poseida"), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced preclinical data demonstrating...